The results using confocal microscopy, followed by unbiassed image analysis and western blotting demonstrated that ELVs reverse hyperphosphorylation of tau at several key residues important biomarkers of AD—pThr181, pSer202/pThr205 (AT8), pThr217, pThr231—while total tau (HT7) does not change with any of the treatments. This evidence concerns the gene MAPT and Alzheimer disease.